Amgen Balance Sheet Health
Financial Health criteria checks 3/6
Amgen has a total shareholder equity of $6.2B and total debt of $57.4B, which brings its debt-to-equity ratio to 924.5%. Its total assets and total liabilities are $89.4B and $83.2B respectively. Amgen's EBIT is $10.3B making its interest coverage ratio 3.4. It has cash and short-term investments of $8.8B.
Key information
924.46%
Debt to equity ratio
US$57.38b
Debt
| Interest coverage ratio | 3.4x |
| Cash | US$8.81b |
| Equity | US$6.21b |
| Total liabilities | US$83.16b |
| Total assets | US$89.37b |
Recent financial health updates
Here's Why Amgen (NASDAQ:AMGN) Has A Meaningful Debt Burden
Nov 26
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26Recent updates
It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year
May 16Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
May 04Amgen: The Biotech That Knows How To Make Money
Apr 17
Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Apr 08 Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.Expanding Oncology Portfolio And International Launches Will Unlock Potential
Apr 08 Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Amgen: Excellent Buy And Hold For A Volatile Market
Mar 31Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 82% Above Its Share Price
Mar 29Amgen: Riding The MariTide Of Monthly Weight Loss
Mar 10Amgen Inc. (NASDAQ:AMGN) Not Flying Under The Radar
Mar 03Amgen Stock: Why I Still Rate It A 'Buy'
Feb 26Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Feb 06Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.38
Feb 01Amgen: Likely To Be Rangebound (Rating Downgrade)
Jan 20Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's
Jan 17Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold
Jan 05Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38
Dec 14Amgen: MariTide Underwhelms, But There Are Ways To Win
Nov 26Here's Why Amgen (NASDAQ:AMGN) Has A Meaningful Debt Burden
Nov 26Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Financial Position Analysis
Short Term Liabilities: AMGN's short term assets ($26.9B) exceed its short term liabilities ($23.0B).
Long Term Liabilities: AMGN's short term assets ($26.9B) do not cover its long term liabilities ($60.2B).
Debt to Equity History and Analysis
Debt Level: AMGN's net debt to equity ratio (782.5%) is considered high.
Reducing Debt: AMGN's debt to equity ratio has increased from 335.8% to 924.5% over the past 5 years.
Debt Coverage: AMGN's debt is well covered by operating cash flow (21.2%).
Interest Coverage: AMGN's interest payments on its debt are well covered by EBIT (3.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 21:44 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amgen Inc. is covered by 64 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |